52

BTMD

Biote Corp($BTMD) Executives and Major Shareholder Signal Bottom with $3.4 Million Buying Spree After 60% Stock Plunge

04/10/2025 20:53

Sentiment

Cluster Buy

Serial Buy

Summary

  • Biote Corp($BTMD) CEO, directors, and major shareholder conducted extensive cluster buying worth approximately $3.4 million during March-April 2025
  • Purchases concentrated at $3-4 price levels after the stock declined 61% from its peak
  • The company reported 6.4% revenue growth in 2024 despite slight net income decrease, with analysts projecting an average target price of $7.47, suggesting 102% upside potential

POSITIVE

  • Large-scale cluster buying ($3.4M+) involving CEO, directors, and major shareholder demonstrates strong management confidence
  • Revenue increased by 6.4% in 2024 with solid operating cash flow of $45.24 million
  • Analysts' average target price of $7.47 suggests 102% upside potential from current levels
  • November 2024 quarter showed EPS of 33 cents, significantly exceeding the 9 cent estimate
  • Current ratio of 1.32 indicates adequate short-term liquidity

NEGATIVE

  • Stock price has declined approximately 61% since July 2024 with recent high volatility
  • Debt level ($110.86 million) is relatively high compared to market capitalization ($192 million)
  • Net income slightly decreased to $3.16 million in 2024 from $3.32 million in 2023
  • March 2025 quarter earnings of 10 cents per share decreased from 18 cents in the same period last year

Expert

Within the healthcare sector, Biote's hormone therapy solutions have long-term growth potential aligned with aging population trends. The extensive insider buying is a significantly positive signal, though high debt ratio and recent earnings volatility are cautionary factors. Regulatory developments and changing competitive dynamics in the hormone replacement therapy market will be crucial variables affecting future stock direction.

Previous Closing Price

$3.46

-0.14(3.76%)

Average Insider Trading Data Over the Past Year

$3.35

Purchase Average Price

$6.55

Sale Average Price

$5.92M

Purchase Amount

$289.93K

Sale Amount

Transaction related to News

Trading Date

Filing Date

Insider

Title

Type

Avg. Price

Trans. Value

05/31/2025

05/31/2025

Sale

$

Key executives and a major shareholder of Biote Corp ($BTMD) have embarked on a significant stock purchasing spree amid a substantial decline in the company's share price in recent weeks. This move signals strong insider confidence in the long-term prospects of the company. $BTMD's stock price, which reached as high as $8.36 in mid-July 2024, has gradually declined to $3.25 in early April 2025, representing a steep drop of approximately 61%. The stock has been on a consistent downward trend since July last year, with one particularly volatile day in mid-March 2025 seeing a single-day plunge of over 25%. Against this backdrop of significant price deterioration, on March 17, 2025, Biote's CEO Bret Christensen purchased 37,595 shares at an average price of $3.87, totaling $145,492. On the same day, board members Stephen Mark Cone and Marc D Beer also bought 38,104 shares ($147,843) and 107,794 shares ($417,162), respectively, at similar price points. Director Andrew Heyer likewise acquired 75,000 shares at $3.95, amounting to $296,028. Following these purchases, major shareholder Guines LLC aggressively accumulated shares between March 13 and April 9, 2025. Guines acquired over 1,085,000 shares worth approximately $3.4 million during this period, including a single transaction of 750,000 shares at $3.22 on March 13. This represents a substantial investment relative to the company's current market capitalization of approximately $192 million. This cluster buying pattern is particularly noteworthy as it concentrated after the stock fell below $4, with consecutive purchases by executives and the major shareholder since mid-March. The timing of these insider purchases coinciding with the stock's lowest points suggests that management views the current stock price as undervalued. Biote Corp is a biotechnology company specializing in hormone optimization through bioidentical hormone replacement pellet therapy. Founded in 2012 and headquartered in Irving, Texas, the company provides a comprehensive platform known as the Biote Method, which includes training and certification for healthcare practitioners, practice management software, inventory management tools, and marketing support. Additionally, the company sells dietary supplements and sterile pellet insertion kits for hormone therapies. Looking at Biote's 2024 financial performance, the company reported a 6.4% year-over-year revenue increase to $197.19 million, primarily driven by growth in procedure revenue. However, net income slightly decreased to $3.16 million from $3.32 million in 2023. Quarterly results have been mixed: the November 2024 quarter showed adjusted earnings of 33 cents per share, significantly exceeding analyst expectations of 9 cents, while the December 2024 quarter reported 10 cents per share, down from 18 cents in the same period the previous year. One concern is the company's debt level of $110.86 million, which is relatively high compared to its market capitalization of $192 million. However, operating cash flow remains solid at $45.24 million, and its current ratio of 1.32 indicates adequate short-term liquidity. Wall Street analysts maintain an overall positive outlook on Biote. The average analyst price target stands at $7.47, suggesting an upside potential of approximately 102.75% from the current price. The consensus rating is 'Strong Buy,' aligning with the recent insider buying activity. Insider purchases of this magnitude are typically interpreted as a strong vote of confidence in a company's long-term value. A cluster buying pattern involving the CEO, board members, and a major shareholder sends an especially powerful signal, as these insiders possess more information about the company's internal operations and future prospects than the average investor. In Biote's case, these substantial insider purchases amid the stock decline likely reflect insiders' belief that the current stock price significantly undervalues the company's intrinsic worth. Particularly, the consecutive buying following the sharp price drop may be interpreted as a bottoming signal. However, investors should also consider risk factors, including the company's debt level and recent quarterly net income decrease. Potential intensifying competition in the bioidentical hormone replacement therapy market and possible regulatory changes also warrant attention. In conclusion, the insider buying activity at Biote Corp represents a strong signal of positive sentiment about the company's value at current price levels. Considering analyst price targets and the magnitude of executive purchases, this could present an attractive entry point for long-term investors, though careful monitoring of the company's financial situation and changing market environment remains advisable.

You can receive notifications when news is published.

news-alarmnews-alarm

Sign up and access more data free.

Sign up and access more data free.

  • Access advanced features of insider transaction screener.

  • Read insider transaction news without any limits.